Genoptix Acquisition Bolsters Novartis' Companion Dx Efforts for Hematology, NSCLC, CRC
January 26, 2011
Genoptix Acquisition Bolsters Novartis' Companion Dx Efforts for Hematology, NSCLC, CRC
The acquisition, announced Jan. 24, "complements the Novartis internal capabilities aimed at improving health outcomes by advancing individualized treatment programs," Novartis said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Asuragen Signs Deal with Novartis to Develop Standardization Tools for BCR-ABL Monitoring
December 8, 2010 / Pharmacogenomics Reporter - Foundation Medicine, MSKCC Partner on Companion Dx for Hematologic Cancer Treatments
May 2, 2013 / GenomeWeb Daily News - Labceutics, Asuragen Conducting BCR-ABL Quality Assurance Study Among European Labs
March 13, 2013 / Pharmacogenomics Reporter - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - People in the News: Matt Winkler, Evan Jones
January 9, 2013 / Clinical Sequencing News